Insider Selling: Natera, Inc. (NASDAQ:NTRA) CFO Sells 1,886 Shares of Stock

Natera, Inc. (NASDAQ:NTRA) CFO Michael Burkes Brophy sold 1,886 shares of the business’s stock in a transaction dated Friday, January 31st. The stock was sold at an average price of $176.60, for a total value of $333,067.60. Following the sale, the chief financial officer now owns 101,811 shares of the company’s stock, valued at $17,979,822.60. The trade was a 1.82 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

Michael Burkes Brophy also recently made the following trade(s):

• On Monday, January 27th, Michael Burkes Brophy sold 1,442 shares of Natera stock. The stock was sold at an average price of $161.87, for a total value of $233,416.54.
• On Friday, January 24th, Michael Burkes Brophy sold 946 shares of Natera stock. The stock was sold at an average price of $171.98, for a total value of $162,693.08.
• On Wednesday, January 22nd, Michael Burkes Brophy sold 25,931 shares of Natera stock. The stock was sold at an average price of $164.97, for a total value of $4,277,837.07.

Natera Price Performance

Shares of NASDAQ NTRA opened at $176.92 on Monday. Natera, Inc. has a 1-year low of $64.74 and a 1-year high of $183.00. The company has a debt-to-equity ratio of 0.33, a current ratio of 4.39 and a quick ratio of 4.23. The business’s fifty day moving average price is $166.89 and its two-hundred day moving average price is $138.50. The firm has a market capitalization of $23.36 billion, a PE ratio of -100.52 and a beta of 1.65.

Natera (NASDAQ:NTRA) last issued its earnings results on Tuesday, November 12th. The medical research company reported ($0.26) earnings per share for the quarter, topping the consensus estimate of ($0.57) by $0.31. Natera had a negative return on equity of 26.23% and a negative net margin of 14.01%. The firm had revenue of $439.80 million for the quarter, compared to analyst estimates of $361.43 million. During the same period last year, the company earned ($0.95) earnings per share. The firm’s revenue for the quarter was up 63.9% on a year-over-year basis. On average, research analysts expect that Natera, Inc. will post -1.56 EPS for the current year.

Institutional Investors Weigh In On Natera

Large investors have recently added to or reduced their stakes in the stock. Blue Trust Inc. increased its position in Natera by 104.3% in the fourth quarter. Blue Trust Inc. now owns 190 shares of the medical research company’s stock worth $30,000 after buying an additional 97 shares during the period. Versant Capital Management Inc grew its stake in shares of Natera by 345.8% in the fourth quarter. Versant Capital Management Inc now owns 214 shares of the medical research company’s stock worth $34,000 after purchasing an additional 166 shares in the last quarter. Quarry LP grew its stake in shares of Natera by 148.4% in the second quarter. Quarry LP now owns 318 shares of the medical research company’s stock worth $34,000 after purchasing an additional 190 shares in the last quarter. Principal Securities Inc. grew its stake in shares of Natera by 20.7% in the fourth quarter. Principal Securities Inc. now owns 344 shares of the medical research company’s stock worth $54,000 after purchasing an additional 59 shares in the last quarter. Finally, Covestor Ltd grew its stake in shares of Natera by 34.3% in the third quarter. Covestor Ltd now owns 372 shares of the medical research company’s stock worth $47,000 after purchasing an additional 95 shares in the last quarter. 99.90% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on NTRA. Leerink Partners upped their price target on Natera from $140.00 to $150.00 and gave the stock an “outperform” rating in a report on Thursday, October 17th. Morgan Stanley upped their target price on Natera from $132.00 to $176.00 and gave the company an “overweight” rating in a research report on Thursday, November 14th. StockNews.com lowered Natera from a “hold” rating to a “sell” rating in a research report on Thursday, November 14th. JPMorgan Chase & Co. upped their target price on Natera from $160.00 to $200.00 and gave the company an “overweight” rating in a research report on Friday, December 13th. Finally, TD Cowen upped their target price on Natera from $155.00 to $175.00 and gave the company a “buy” rating in a research report on Wednesday, November 13th. One research analyst has rated the stock with a sell rating and seventeen have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Natera currently has a consensus rating of “Moderate Buy” and a consensus price target of $165.88.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.